Navigation Links
Kinex Pharmaceuticals' Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Society's 2013 Honoree for its Cuisine for a Cure event
Date:4/12/2013

BUFFALO, N.Y., April 12, 2013 /PRNewswire/ -- Kinex Pharmaceuticals announced that Dr. David Hangauer , co-founder and Chief Scientific Officer of Kinex, has been named the American Cancer Society's 2013 Honoree of the year for its Cuisine for a Cure event. 

"I am honored to be the 2013 honoree for the American Cancer Society Cuisine for a Cure event.  I have devoted much of my career to discovering better drugs for treating cancer, two of which have recently advanced to clinical trials.  Through these efforts I am constantly humbled by the courage and strength of the cancer patients.  To be able to work on such an important medical need is a privilege," said Dr. David Hangauer .

"Kinex was initially founded upon a scientific platform to develop better drugs for treating cancer.  This is not solely a professional endeavor for us.  Importantly, our company is driven by a deep personal commitment as we have all been touched by both the devastation of cancer and the hope and extended life that new compounds can bring when fighting the disease.  Dave is the foundation of our efforts in Kinex.  Progress in treatment regimens will continue as extremely productive and engaged scientists like Dr. David Hangauer lead the charge in the fight against cancer," quoted Dr. Allen Barnett , President Emeritus of Kinex. 

Dr. Johnson Lau , CEO of Kinex, commented, "Both patients and Kinex are fortunate to have Dr. Hangauer dedicated to the field of cancer.  His expertise in drug discovery, coupled with tireless effort and commitment, has generated two very promising novel compounds for the treatment of various tumor types that Kinex and our drug development partners, Hanmi Pharmaceuticals, Xiangxue Pharmaceuticals, and PharmaEssentia are actively pursuing.  His focus on improving patient's lives through the discovery and development of new and better drugs is well reflected by the recognition of his achievements at the American Cancer Society 2013 event.  Kinex is proud to have Dave as our cofounder and Chief Scientific Officer."

Kinex Inquiries:

Patrick Gallagher
Vice President, Business Development and Investor Relations
Kinex Pharmaceuticals
701 Ellicott Street
Buffalo, NY 14203
pgallagher@kinexpharma.com


'/>"/>
SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
2. Kinex Pharmaceuticals Receives Substantial Strategic Investment
3. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
4. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Korea , Jan. 24, 2017 Mezzion ... in New Jersey State court alleging that Dr. Reddy,s ... in its Food and Drug Administration (FDA) cGMP practices, ... that Dr. Reddy,s repeatedly represented to Mezzion that it ... its misconduct from Mezzion.  The suit also states that ...
(Date:1/24/2017)... 2017 The global  active pharmaceutical ingredients (API) market ... based on a new report by Grand View Research, Inc. The rising ... the market over the forecast period. Advancements in recombinant molecular technologies and ... growth.  Continue Reading ... ...
(Date:1/24/2017)... January 24, 2017 Aptuit, LLC, ... Surgical Laboratory des Massachusetts General Hospital (MGH) unter Leitung ... es um die Identifizierung und Validierung neuartiger Targets in ... sie der Resistenz von Antibiotika bei der Behandlung schwerer ... ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... , ... Center for Hispanic Leadership (CHL) Academy , the talent development ... Employee & Labor Relations at City of Hope , a world-renowned independent research ... City of Hope is committed to stay out in front of its communities’ growing ...
(Date:1/24/2017)... Iowa City, IA (PRWEB) , ... January 24, 2017 , ... ... in the country, has taken great care to design a program that provides teachers ... language abroad and domestically. This online teaching certificate is ideal for post-baccalaureate students and ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The NewKILO JRP, ... Institutes (NMIs) and co-funded by the European Union (EU), was completed in May 2015. ... vacuum, instead being maintained and used in air, which presents some challenges to establishing ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... water, has officially unveiled its latest award-winning bottles, designed specifically to optimize the ... , Taza Agua is renowned for introducing the world’s first untouched bottled ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Speaking With God’s Voice”: a resolute ... the creation of published author, Louis A. Miraglia, a born-again believer, who spent his ... God’s great, impactful Word. , “There is little doubt that God Himself prepared ...
Breaking Medicine News(10 mins):